• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mural Oncology Announces Sanction of the Scheme by the High Court

    12/3/25 4:30:00 PM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURA alert in real time by email

    WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), will acquire the entire issued and to be issued share capital of Mural (the "Acquisition").

    The Scheme and the Acquisition will become effective on delivery of the Court Order to the Irish Registrar of Companies.

    Delivery of the Court Order to the Irish Registrar of Companies is expected to occur, and the Acquisition is expected to become effective, on 5 December 2025 (the "Effective Date"). Accordingly, 4 December 2025 is expected to be the last date on which trading of Mural Shares on the Nasdaq will occur. Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market is expected to occur with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.

    Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, subject to the delivery of the Court Order to the Irish Registrar of Companies on 5 December 2025, all consideration payable by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.

    Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law.

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

    FOR IMMEDIATE RELEASE

    Enquiries

    Mural Oncology plc

    [email protected]

    Lucid Capital Markets, LLC (Financial Adviser to Mural)

    570 Lexington Ave, 40th Floor

    New York, NY 10022

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this announcement regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "believe", "will", "may", "would", "could" or "should" or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding Mural, XOMA Royalty and Sub's intention to consummate the Acquisition and the expected timing of the closing of the Acquisition.

    These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: uncertainties as to the possibility that closing conditions for the Acquisition may not be satisfied or waived; the expected timing of the payment of the consideration paid by Sub to Scheme Shareholders; the expected timing of the cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market; the other risks and uncertainties pertaining to Mural's business, including those described in Mural's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") and definitive proxy statement filed with the SEC on 23 September 2025, as well as Mural's subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

    Statements Required by the Irish Takeover Rules 

    The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

    Lucid, which is authorized and regulated by the SEC and the Financial Industry Regulatory Authority ("FINRA") in the United States, is acting as financial adviser exclusively for Mural and for no one else in connection with the subject matter of this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Mural for providing the protections afforded to clients of Lucid or its affiliates, nor for providing advice in relation to any matter referred to in this announcement. Neither Lucid nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lucid in relation to the matters in this announcement, any statement or other matter or arrangement referred to herein or otherwise.

    Davy Corporate Finance, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance or for providing advice in connection with the matters referred to in this announcement.

    Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP are acting as legal advisers on U.S. and Irish law matters respectively to Mural, and Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP are acting as legal advisers on U.S. and Irish law matters respectively to XOMA Royalty and Sub.

    Disclosure Requirements of the Irish Takeover Rules

    Under Rule 8.3(b) of the Irish Takeover Rules, any person who is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Mural must disclose all "dealings" in such "relevant securities" during the "offer period". The disclosure of a "dealing" in "relevant securities" by a person to whom Rule 8.3(b) applies must be made by no later than 3:30pm (U.S. Eastern Time) on the "business day" following the date of the relevant "dealing". A dealing disclosure must contain the details specified in Rule 8.6(b) of the Irish Takeover Rules, including details of the dealing concerned and of the person's interests and short positions in any "relevant securities" of Mural.

    All "dealings" in "relevant securities" of Mural by a bidder, or by any party acting in concert with a bidder, must also be disclosed by no later than 12:00 noon (U.S. Eastern Time) on the "business day" following the date of the relevant "dealing".

    If two or more persons co-operate on the basis of an agreement, either express or tacit, either oral or written, to acquire an "interest" in "relevant securities" of Mural, they will be deemed to be a single person for the purpose of Rule 8.3(a) and (b) of the Irish Takeover Rules.

    A disclosure table, giving details of the companies in whose "relevant securities" dealing disclosures should be made, can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.

    "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

    Terms in quotation marks in this section are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel's website.

    If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.

    General

    The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.

    Publication on a Website

    In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural's website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.



    Primary Logo

    Get the next $MURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURA
    $XOMA

    CompanyDatePrice TargetRatingAnalyst
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    Mural Oncology plc
    $MURA
    3/25/2025Overweight → Equal-Weight
    Morgan Stanley
    Mural Oncology plc
    $MURA
    3/25/2025$18.00Strong Buy → Outperform
    Raymond James
    Mural Oncology plc
    $MURA
    6/28/2024$15.00Buy
    Rodman & Renshaw
    XOMA Royalty Corporation
    $XOMA
    4/29/2024$40.00Outperform
    Leerink Partners
    Mural Oncology plc
    $MURA
    4/4/2024$13.00Overweight
    Morgan Stanley
    XOMA Royalty Corporation
    $XOMA
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    XOMA Royalty Corporation
    $XOMA
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    More analyst ratings

    $MURA
    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hughes Owen bought $2,505,000 worth of Depositary Shares - 8.375% B Cumulative Stock (100,000 units at $25.05), increasing direct ownership by 5,000% to 102,000 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    12/8/25 4:30:18 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hickey Benjamin

    4 - Mural Oncology plc (0001971543) (Issuer)

    12/5/25 9:16:59 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Loew Caroline returned 293,059 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    12/5/25 9:10:35 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hughes Owen bought $2,505,000 worth of Depositary Shares - 8.375% B Cumulative Stock (100,000 units at $25.05), increasing direct ownership by 5,000% to 102,000 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    12/8/25 4:30:18 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/9/25 4:44:30 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MURA
    $XOMA
    SEC Filings

    View All

    $MURA
    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

    – Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda's externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda through a strategic royalty share transaction. Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced, and XOMA Royalty will receive payments based

    12/30/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or

    12/22/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc

    SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

    12/16/25 9:53:36 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Mural Oncology plc

    15-12G - Mural Oncology plc (0001971543) (Filer)

    12/15/25 4:30:46 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Mural Oncology plc

    EFFECT - Mural Oncology plc (0001971543) (Filer)

    12/9/25 12:15:09 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Morgan Stanley

    Morgan Stanley downgraded Mural Oncology from Overweight to Equal-Weight

    3/25/25 12:58:54 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Raymond James with a new price target

    Raymond James downgraded Mural Oncology from Strong Buy to Outperform and set a new price target of $18.00

    3/25/25 11:43:59 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

    Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

    11/13/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

    Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

    9/26/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

    WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

    9/23/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

    – Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda's externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda through a strategic royalty share transaction. Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced, and XOMA Royalty will receive payments based

    12/30/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or

    12/22/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/14/24 5:15:53 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/12/24 3:52:44 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/4/24 2:39:13 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care